Clinical Trials - March 15, 2026
Oslo University Hospital begins study with TikoMed’s drug candidate
Oslo University Hospital has begun the inclusion of patients in the IMPACT study, which aims to investigate the efficacy and safety of TikoMed’s candidate drug ILB compared to riluzole for the treatment of ALS.
Clinical Trials - March 9, 2026
Oncopeptides secures fast-track designation for Window-of-Opportunity study
Oncopeptides has achieved key regulatory agreement with both the Swedish and Norwegian Medical Products Agencies regarding the design of its planned “Window-of-Opportunity” study evaluating a Peptide Drug Conjugate (PDC) in glioblastoma.
Clinical Trials - February 10, 2026
Lundbeck presents real-world data highlighting improvements in migraine
The company has announced six-month data from the 12-month, real-world INFUSE study, evaluating the effectiveness of Vyepti in adults with migraine who had failed at least one preventive anti-calcitonin gene–related peptide (aCGRP) treatment, at any time point previously.
Clinical Trials - February 2, 2026
SynAct Pharma initiates Phase 2 study in respiratory insufficiency
SynAct Pharma has initiated a Phase 2 study (RESPIRE) with resomelagon in patients hospitalized with respiratory insufficiency due to viral infections.
Clinical Trials - January 27, 2026
Takeda’s zasocitinib meets primary and secondary endpoints in Phase 3 study
The results showed that approximately 30 percent of patients achieved complete skin clearance (PASI 100) at week 16, and that more than half reached almost complete clearance (PASI 90).
Clinical Trials - January 27, 2026
DexTech Medical’s myeloma study, completed at the end of February
The results show that all patients responded positively to the ODX treatment, with a transition from progressive disease to stable disease.
